TG Therapeutics Inc (TGTX)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 1.75 | 2.09 | 2.00 | 1.88 | 3.36 | 3.51 | 3.16 | 2.85 | — | — | — | 29.82 | — | — | — | 16.77 | — | — | — | — |
| Receivables turnover | 2.55 | 2.27 | 4.07 | 4.31 | 4.35 | 4.60 | 1.08 | 0.73 | — | — | 79.10 | 8.76 | 4.82 | 3.18 | 2.59 | 1.18 | — | — | — | — |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 0.69 | 0.58 | 1.21 | 1.07 | 0.84 | 0.69 | 0.14 | 0.05 | 0.02 | 0.03 | 0.04 | 0.04 | 0.03 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
The inventory turnover ratio for TG Therapeutics Inc has shown fluctuation over the years, ranging from 1.88 to 29.82. A higher inventory turnover ratio indicates that the company is selling its products more efficiently.
Regarding receivables turnover, the company's performance has varied significantly, with values ranging from 0.73 to 79.10. A higher receivables turnover ratio suggests that the company is collecting its receivables more quickly.
The payables turnover ratio has not been provided in the data, indicating a lack of information on the company's ability to pay its suppliers.
In terms of working capital turnover, TG Therapeutics Inc has shown improvement over the years, with values increasing from 0.01 to 1.21. A higher working capital turnover ratio indicates that the company is effectively utilizing its working capital to generate sales.
Overall, it is important for TG Therapeutics Inc to maintain efficient turnover ratios in inventory, receivables, and working capital to ensure optimal operational performance and financial health.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 209.13 | 174.33 | 182.77 | 194.48 | 108.50 | 104.08 | 115.38 | 128.09 | — | — | — | 12.24 | — | — | — | 21.77 | — | — | — | — |
| Days of sales outstanding (DSO) | days | 143.32 | 161.00 | 89.60 | 84.63 | 83.87 | 79.34 | 338.10 | 497.14 | — | — | 4.61 | 41.66 | 75.79 | 114.65 | 140.77 | 310.27 | — | — | — | — |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Based on the provided data for TG Therapeutics Inc, the analysis of activity ratios reveals important insights into the company's efficiency in managing its operating cycle.
1. Days of Inventory on Hand (DOH):
- The DOH measures how many days, on average, the company holds inventory before selling it.
- TG Therapeutics Inc showed an improvement in inventory management from 21.77 days in March 2021 to 12.24 days in March 2022.
- However, the trend reversed dramatically in the subsequent periods, with DOH increasing significantly to 194.48 days by March 2024, indicating potential issues in inventory control and liquidity.
2. Days of Sales Outstanding (DSO):
- DSO reflects the average number of days it takes for the company to collect revenue after making a sale.
- TG Therapeutics Inc experienced fluctuations in DSO, with a significant decrease from 310.27 days in March 2021 to 4.61 days in June 2022, indicating an improvement in receivables management.
- However, DSO increased again in the following periods, reaching 143.32 days by December 2024, suggesting a delay in collecting revenue and potential credit risk concerns.
3. Number of Days of Payables:
- The number of days of payables shows how long, on average, the company takes to pay its suppliers.
- The data provided indicates that TG Therapeutics Inc did not have any payables outstanding during the periods reported, which might be an indication of the company's payment terms or strategies.
In conclusion, the analysis of activity ratios for TG Therapeutics Inc suggests that while the company demonstrated improvements in inventory and receivables management in certain periods, there are challenges such as increasing DOH and DSO levels that may require attention to enhance operational efficiency and maintain healthy cash flows.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | — | — | — | 4,246.27 | 2,340.45 | 1,360.02 | 91.63 | 26.71 | 9.07 | 13.36 | 15.57 | 15.04 | 11.15 | 7.34 | 4.04 | 1.86 | 0.32 | 0.40 | 0.46 | 0.48 |
| Total asset turnover | 0.57 | 0.45 | 0.85 | 0.75 | 0.67 | 0.55 | 0.09 | 0.03 | 0.01 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
TG Therapeutics Inc's fixed asset turnover ratio has shown significant fluctuations over the years. The ratio was consistently low from March 2020 to December 2022, indicating that the company was not efficiently utilizing its fixed assets to generate sales. However, starting from March 2023, there was a substantial increase in the ratio, reaching a peak of 4,246.27 by December 31, 2024. This suggests a significant improvement in the company's ability to generate sales revenue from its fixed assets.
In contrast, the total asset turnover ratio remained extremely low from March 2020 to December 2022, indicating poor efficiency in utilizing all assets to generate revenue. The ratio started to show slight improvement from March 2023, reaching 0.85 by June 30, 2024. This indicates that the company is gradually becoming more efficient in generating sales relative to its total assets.
Overall, the analysis of TG Therapeutics Inc's long-term activity ratios suggests that the company has made significant improvements in asset utilization efficiency, particularly in the more recent periods. By increasing its fixed asset turnover and total asset turnover ratios, the company has shown progress in effectively generating revenue from its assets.